08 jun: UBS Racks Up to $350 Million in Losses Related to Facebook IPO -S..
08 jun: Colombian Stocks Decline, Led By Ecopetrol; Peso Weakens
08-06-2012 23:47:00

J&J to Record $600 Million Charge Tied to Outstanding Lawsuits

Relateret indhold
Relateret debat
04 mar - 
Sir,Ma We can deliver financial service/instrument(BG/S..
02 mar - 
Dear Sir/Ma, We are direct providers of Fresh Cut BG, S..
24 feb - 
We arrange Following Bank Instruments Letter of Credit ..

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:47 ET (21:47 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Jyske: Analytikere skruer ned for forventningerne til 2015

05-03-2015 15:15:01
Analytikerne er i samlet flok blevet en anelse mere skeptiske omkring Jyske Banks evne til at tjene penge i 2015, efter at bankens regnskab for de sidste tre må..

FLS-kollega nedjusterer forventningerne

05-03-2015 12:51:55
Den amerikanske ingeniørkoncern Joy Global, der lige som danske FLSmidth leverer til den globale mineindustri, nedjusterer i torsdagens kvartalsregnskab sine fo..

Genmab/Sydbank: Går til tops efter milliardhandel i branchen

05-03-2015 09:45:30
Genmab stiger markant fra morgenstunden torsdag, og det kan ifølge Sydbank meget vel skyldes en giganthandel i USA, hvor medicinalselskabet Abbvie natten til to..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
NNIT: Udbud af aktier lukker kl.12 torsdag - NY
2
Vestas udsteder obligation til 500 mio. euro
3
Bavarian/Nordea: Kursmålet skrues kraftigt i vejret
4
Bavarians kursmål løftes af flere finanshuse efter aftale
5
Bavarian/Jyske: Hæver kursmål med 48 pct. efter Prostvac-aftale

Relaterede aktiekurser

Johnson & Johnson 102,69 1,0% Stigning i aktiekurs
Omnicare Inc 75,75 0,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
5. marts 2015 17:03:35
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB6 - 2015-03-05 17:03:35 - 2015-03-05 17:03:35 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x